Skip to content

EBITDA margin at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
22.1%+0.3pp
Stryker logo
StrykerSYK
24.6%+4.7pp
IAR
Integra LifeSciencesIART
-19.5%-30.1pp
Solventum logo
SolventumSOLV
31.5%+15.2pp
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-3%-1.1pp
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-63.2%-1.4pp

Other financials

Income statement

See full
Revenue$27.8M+18.6%
Gross profit$25.9M+19.8%
Operating income$2.6M+221%
Net income$459.0K+113%
EPS (diluted)$0.05+112%

Balance sheet

See full
Cash & equivalents$13.6M-34.3%
Total debt$48.4M+8.2%
Total equity$7.0M-80.8%
Total assets$69.3M-28.1%

Cash flow

See full
Operating cash flow-$2.5M-23.3%
CapEx$43.8K-97.5%
Free cash flow-$2.5M+32.6%

Valuation

See full
Market cap$216.18M-9.7%
Enterprise value$250.95M-6.5%
P/S-0.5×

Profitability

See full
Gross margin92.9%+1.8pp
Operating margin6.1%+5.1pp
Net margin-31.2%-93.4pp
FCF margin-9.8%-3.5pp

Returns & leverage

See full
Return on equity-153.7%-199pp
Debt / equity6.9×+5.7×
Current ratio2.3×-0.5×

Where this comes from

Calculated from Sanara MedTech Inc.’s reported figures.

Based on trailing twelve months.

The official record: Sanara MedTech Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sanara MedTech Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sanara MedTech Inc.'s EBITDA margin?
Sanara MedTech Inc. (SMTI) reported EBITDA margin of 9.3% in Q1 2026.
How has Sanara MedTech Inc.'s EBITDA margin changed year-over-year?
Sanara MedTech Inc.'s EBITDA margin increased by 44.1% year-over-year, from 6.5% to 9.3%.
What is the long-term trend for Sanara MedTech Inc.'s EBITDA margin?
Over 5 years (2020 to 2025), Sanara MedTech Inc.'s EBITDA margin has grown at a -19.8% compound annual growth rate (CAGR), from -25.6% to 8.5%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.